The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia

被引:0
作者
Nakano, Hirofumi [1 ]
Fujiwara, Shin-ichiro [1 ]
Ito, Shoko [1 ]
Mashima, Kiyomi [1 ]
Umino, Kento [1 ]
Minakata, Daisuke [1 ]
Yamasaki, Ryoko [1 ]
Kawasaki, Yasufumi [1 ]
Sugimoto, Miyuki [1 ]
Ashizawa, Masahiro [1 ]
Yamamoto, Chihiro [1 ]
Hatano, Kaoru [1 ]
Okazuka, Kiyoshi [1 ]
Sato, Kazuya [1 ]
Oh, Iekuni [1 ]
Ohmine, Ken [1 ]
Suzuki, Takahiro [1 ]
Muroi, Kazuo [1 ]
Kanda, Yoshinobu [1 ]
机构
[1] Jichi Med Univ, Div Hematol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan
关键词
acute myeloid leukemia; prognostic factors; induction chemotherapy; early clearance; blast cell; peripheral blood; ACUTE LYMPHOBLASTIC-LEUKEMIA; AML; 10; TRIAL; COMPLETE REMISSION; FIXED-SCHEDULE; BONE-MARROW; THERAPY; PREDICTS; CYTARABINE; DAUNORUBICIN; MULTICENTER;
D O I
10.1002/hon.2277
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The early clearance of blast cells in peripheral blood (PB) during induction chemotherapy can predict the clinical outcome in acute leukemia. We retrospectively analyzed the kinetics of white blood cell (WBC) count, blast cell percentage (BCP), and blast cell count (BCC) in PB in 78 patients with de novo acute myeloid leukemia who underwent a uniform induction chemotherapy between December 2001 and December 2015 at Jichi Medical University. By a repeated-measures analysis of variance, the interaction of the decline in BCP with the achievement of complete remission (CR) was stronger than those of the decline in WBC or BCC. A receiver operating characteristic curve analysis for the achievement of CR showed that the areas under the curve for the decline in WBC, BCP, and BCC were 0.592, 0.703, and 0.634, respectively, and a decline in BCP of 9.25%/day within 4 or 5days from induction chemotherapy was the optimal cutoff value. A multivariate analysis showed that a rapid decline in BCP (9.25%/day) was a significant predictive factor for CR, independent of the cytogenetic risk (p=0.0096). A rapid decline in BCP during the first 5days of induction chemotherapy may be a good predictor of CR. Copyright (c) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:357 / 364
页数:8
相关论文
共 29 条
  • [11] Peripheral blood blast clearance during induction therapy in acute myelold leukemia
    Gianfaldoni, Giacomo
    Marinelli, Francesco
    Bencini, Sara
    Leoni, Franco
    Baldini, Simone
    Bosi, Alberto
    [J]. BLOOD, 2008, 111 (03) : 1746 - 1747
  • [12] The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
    Grimwade, D
    Walker, H
    Oliver, F
    Wheatley, K
    Harrison, C
    Harrison, G
    Rees, J
    Hann, I
    Stevens, R
    Burnett, A
    Goldstone, A
    [J]. BLOOD, 1998, 92 (07) : 2322 - 2333
  • [13] HIDDEMANN W, 1982, BLOOD, V59, P216
  • [14] Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study
    Holowiecki, Jerzy
    Grosicki, Sebastian
    Giebel, Sebastian
    Robak, Tadeusz
    Kyrcz-Krzemien, Slawomira
    Kuliczkowski, Kazimierz
    Skotnicki, Aleksander B.
    Hellmann, Andrzej
    Sulek, Kazimierz
    Dmoszynska, Anna
    Kloczko, Janusz
    Jedrzejczak, Wieslaw W.
    Zdziarska, Barbara
    Warzocha, Krzysztof
    Zawilska, Krystyna
    Komarnicki, Mieczyslaw
    Kielbinski, Marek
    Piatkowska-Jakubas, Beata
    Wierzbowska, Agnieszka
    Wach, Malgorzata
    Haus, Olga
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) : 2441 - 2448
  • [15] Investigation of the freely available easy-to-use software 'EZR' for medical statistics
    Kanda, Y.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 (03) : 452 - 458
  • [16] Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia:: data from the German AML Cooperative Group (AMLCG) 1992 Trial
    Kern, W
    Haferlach, T
    Schoch, C
    Löffler, H
    Gassmann, W
    Heinecke, A
    Sauerland, MC
    Berdel, W
    Büchner, T
    Hiddemann, W
    [J]. BLOOD, 2003, 101 (01) : 64 - 70
  • [17] Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study
    Lacombe, F.
    Arnoulet, C.
    Maynadie, M.
    Lippert, E.
    Luquet, I.
    Pigneux, A.
    Vey, N.
    Casasnovas, O.
    Witz, F.
    Bene, M. C.
    [J]. LEUKEMIA, 2009, 23 (02) : 350 - 357
  • [18] Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study
    Ohtake, Shigeki
    Miyawaki, Shuichi
    Fujita, Hiroyuki
    Kiyoi, Hitoshi
    Shinagawa, Katsuji
    Usui, Noriko
    Okumura, Hirokazu
    Miyamura, Koichi
    Nakaseko, Chiaki
    Miyazaki, Yasushi
    Fujieda, Atsushi
    Nagai, Tadashi
    Yamane, Takahisa
    Taniwaki, Masafumi
    Takahashi, Masatomo
    Yagasaki, Fumiharu
    Kimura, Yukihiko
    Asou, Norio
    Sakamaki, Hisashi
    Handa, Hiroshi
    Honda, Sumihisa
    Ohnishi, Kazunori
    Naoe, Tomoki
    Ohno, Ryuzo
    [J]. BLOOD, 2011, 117 (08) : 2358 - 2365
  • [19] Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study
    Ohtake, Shigeki
    Miyawaki, Shuichi
    Kiyoi, Hitoshi
    Miyazaki, Yasushi
    Okumura, Hirokazu
    Matsuda, Shin
    Nagai, Tadashi
    Kishimoto, Yuji
    Okada, Masaya
    Takahashi, Masatomo
    Handa, Hiroshi
    Takeuchi, Jin
    Kageyama, Shinichi
    Asou, Norio
    Yagasaki, Fumiharu
    Maeda, Yasuhiro
    Ohnishi, Kazunori
    Naoe, Tomoki
    Ohno, Ryuzo
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (02) : 276 - 283
  • [20] Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia
    Panzer-Grümayer, ER
    Schneider, M
    Panzer, S
    Fasching, K
    Gadner, H
    [J]. BLOOD, 2000, 95 (03) : 790 - 794